Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.
We are pleased to announce that a number of BioMed Central journals have come together to create a new cross-journal series on translational oncology.
The series is now accepting submissions of research articles that provide important developments in cancer research. Preclinical studies should provide a significant advance in knowledge, and have clear potential for strong clinical impact.
This webcast provides the latest information on the current and emerging treatment formats which could improve outcomes for patients with STS, the standards of care for patients with STS and how these are best met within the context of a multidisciplinary team.
Assess the new treatment and diagnosis paradigms for A-STS and explain how to best apply them to their daily practice.
Explain the current best practice for providing treatment STS within the context of the multidisciplinary team.
Dr Paolo G Casali is head of the Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. He serves as Secretary of the Ethics Committee of his institution. His research focuses on rare tumors, especially adult sarcomas, including gastrointestinal stromal tumors (GIST), and uncommon histological types. He is the Secretary of the Italian Sarcoma Group, and is a member of the EORTC Soft Tissue & Bone Sarcoma Group. He chairs the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which endeavours to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers. He acts as an Editor of START, an Italian-based, European state-of-the-art instrument on cancer treatment. He is a member of the Executive Board of ESMO as chair of the Public Policy/European Affairs Committee, and is Faculty Coordinator for Sarcoma. He is a member of the Policy Committee of ECCO. He teaches Medical Therapy of Rare Cancers at the Milan University postgraduate school in Oncology.
Dr. Angelo Paolo Dei Tos is the Director of the Department of Oncology and Director of Anatomic Pathology at the General Hospital in Treviso, Italy, and Contract Professor of Pathology at the University of Padua School of Medicine. He is the Chairman of the Pathology Subcommittee of the Soft Tissue and Bone Group of EORTC, Founder and Past Chairman of the Working Group on Soft Tissue Tumor Pathology of the European Society of Pathology, Past President of the International Society of Bone and Soft Tissue Pathology, panel member for the WHO classification of Bone and Soft Tissue Sarcomas, member of the Board of Directors of the Connective Tissue Oncologic Society, and a faculty member of ESMO. He has authored or co-authored more than 140 peer reviewed scientific papers.
The journal is an integral part of the euroSARC project funded by the European Commission through the 7th Framework Programme under Grant Agreement no. 278742.
By using this website, you agree to our Terms and Conditions, Privacy statement and Cookies policy. Manage the cookies we use in the preference centre.
© 2019 BioMed Central Ltd unless otherwise stated. Part of Springer Nature.
